Forbes April 15, 2021
Amy Feldman

It’s hard to flawlessly churn out billions of doses of drugs – and we aren’t doing a great job of it. A Midas List VC pulled together a dream team that says it’s come up with a better, faster way.

It’s all come down to Pfizer and Moderna. With Johnson & Johnson’s “one-and-done” shot on pause, America’s race against the virus and its variants now relies on our ability to flawlessly manufacture hundreds of millions of doses of the new mRNA vaccines – at warp speed. And previous quality control issues at a Pfizer plant, on top of Emergent BioSolutions fiasco with the J&J vaccine, are a stark reminder that manufacturing medicine is not easy.

Robert Nelsen, the top biotech...

Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Public Health
From big tech to small tech: A health care visionary pushes for a patient-centric approach to technology
Innovation Without Bounds
Dell Medical School developing technology to improve access to health care for homeless population
Telehealth 2050: The future design of virtual care technology
Smart Technologies Create a More Connected Environment for Older Adults

Today's Sponsors

Curation Health

Today's Sponsors


Today's Sponsor